Harrow Health ( (HROW) ) has released its Q1 earnings. Here is a breakdown of the information Harrow Health presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Harrow, Inc. is a prominent North American eyecare pharmaceutical company focused on the development and commercialization of innovative ophthalmic products, aiming to make these accessible and affordable to millions of patients annually.
In its first-quarter 2025 earnings report, Harrow announced a significant revenue increase of 38% year-over-year, reaching $47.8 million, driven by the successful launch of the VEVYE Access for All program. Despite a GAAP net loss of $17.8 million, the company achieved a record cash flow from operations of $19.7 million.
Key financial highlights include a 35% increase in VEVYE revenues compared to the previous quarter, reaching $21.5 million. The company’s cash and cash equivalents stood at $66.7 million as of March 31, 2025. Harrow’s strategic initiatives, including the VEVYE Access for All program, have shown promising early results, with prescription volumes and prescriber numbers significantly increasing.
Looking ahead, Harrow’s management remains optimistic about achieving its 2025 revenue target of over $280 million, supported by the growing demand for its product portfolio and potential strategic acquisitions. The company is committed to enhancing its U.S. commercial platform with high-quality ophthalmic pharmaceutical assets.